Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization
AssigneeP. Doina International Ltd.
InventorDoina Filip
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and a method for immunization of mammals against atherosclerosis including steps of a) obtaining blood from a mammal; b) isolating low density lipoprotein from the blood; c) fusing the lipoprotein in vitro to obtain heavy microemulsion lipoprotein fusion particles having new antigenic determinants; d) administering the fusion particles obtained in step (c) to a mammal; and e) allowing the immune system to clear fusion lipoprotein particles from the mammal.
Claims14
A method for immunization of mammals against atherosclerosis comprising the steps of:
- a) obtaining blood from said mammal;
- b) isolating low density lipoprotein from said blood;
- c) fusing said lipoprotein in vitro to obtain heavy microemulsion lipoprotein fusion particles having a flotation density of 1.20-1.24 g/ml and having new antigenic determinants;
- d) administering said fusion particles obtained in step (c) to a mammal;
- e) allowing the removal of heavy microemulsion particles from atherosclerotic lesions by immune mechanisms from said mammal.
A pharmaceutical composition for the treatment of atherosclerosis and for prophylaxis of atherosclerosis comprising as an active ingredient a reorganized lipid material comprising heavy microemulsion particles having a flotation density of 1.20-1.24 g/ml and having new antigenic determinants which originated from the animal to be treated, and a conventional immunization adjuvant product.
A method for the preparation of a pharmaceutical composition for the treatment of atherosclerosis and for the prophylaxis of atherosclerosis comprising as an active ingredient a reorganized lipid material comprising heavy microemulsion particles having a flotation density of 1.20-1.24 g/ml and having new antigenic determinants which originated from the animal to be treated, and a conventional immunization adjuvant product comprising the steps:
- a) obtaining a fusion lipoprotein by adding an amphipathic material to a patient's lipoprotein in a fusion buffer in vitro to fuse said lipoprotein;
- and
- b) removing said amphipathic material to isolate said lipoprotein fusion product comprising heavy microemulsion particles having a flotation density of 1.20-1.24 g/ml at having new antigenic determinants and transfer it to a physiological saline by dialysis.
Dependencies are inferred from the claim text.